Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease [PDF]
, 2015 AIMS: To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and investigate whether early treatment responses can predict long-term outcomes, during a ...
Farlow, Martin R. +4 more
core +1 more source
A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model. [PDF]
, 2018 We describe here the results from the testing of a small molecule first-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, A03, that increases the levels of the neuroprotective enzyme SirT1 while not affecting levels of neurotoxic ...
Bai, Dongsheng +14 more
core +3 more sources
Memantine as an Augmentation Therapy for Anxiety Disorders
Case Reports in Psychiatry, 2012 Objective. Glutamate, an excitatory neurotransmitter in the central nervous system (CNS), may play a role in the development of anxiety. Memantine partially blocks N-methyl-D-aspartate (NMDA) receptors' glutamate channels located in the CNS.
Thomas L. Schwartz +2 more
doaj +1 more source
Memantine has no effect on KATP channels in pancreatic β cells
BMC Research Notes, 2018 Objective Memantine, a drug for Alzheimer’s disease, is considered to suppress excessive stimulation of N-methyl-d-aspartic acid receptors and to prevent neuronal death.
Ryota Imai +6 more
doaj +1 more source
Ketamine: NMDA receptors and beyond [PDF]
, 2016 Human studies examining the effects of the dissociative anesthetic ketamine as a model for psychosis and as a rapidly acting antidepressant have spurred great interest in understanding ketamine's actions at molecular, cellular, and network levels ...
Izumi, Yukitoshi +2 more
core +2 more sources
Evaluating High-Dose Rivastigmine Patch in Severe Alzheimer’s Disease: Analyses with Concomitant Memantine Usage as a Factor [PDF]
, 2015 Background: ACTION, a 24-week, prospective, randomized, parallel-group, double-blind study in patients with severe Alzheimer’s disease (AD), demonstrated significant efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on the Severe Impairment ...
Farlow, Martin R. +3 more
core +1 more source
Effectiveness of the Combination of Memantine Plus Vitamin D on Cognition in Patients With Alzheimer Disease: A Pre-Post Pilot Study [PDF]
, 2012 Objective: To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD).
B. Brugg +4 more
core +5 more sources
Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. [PDF]
PLoS ONE, 2012 BackgroundAgitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and ...
Chris Fox +9 more
doaj +1 more source
In vivo study of pharmacokinetic parameters of a new combination drug based on citicoline and memantine [PDF]
Research Results in Pharmacology, 2021 Introduction: Cognitive impairment (dementia) is one of the most common pathologies with increasing numbers of patients. Most often they are the symptoms of Alzheimer’s disease and vascular brain diseases, for which such drugs as memantine and citicoline
Boris B. Sysuev, Damir K. Salakhetdinov
doaj +3 more sources
Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. [PDF]
, 2016 BACKGROUND: Refractory migraine is a challenging condition with great impact on health related quality of life. Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions.
Ashina, Sait +3 more
core +3 more sources